Alvotech is a biotechnology company focused on developing and manufacturing biosimilars, which are biologic medical products highly similar to already approved reference products. Its core offerings include a range of biosimilar candidates targeting various therapeutic areas, primarily in immunology and oncology. The company operates in the healthcare sector, with major revenue sources stemming from partnerships and licensing agreements for its biosimilar products.
The investment profile of Alvotech is more aligned with growth investors, given its focus on developing innovative biosimilars in a competitive market. The company currently does not offer dividends, and its financial performance indicates potential for future growth, albeit with associated risks. This profile may appeal to investors looking for exposure to the biotechnology sector with a medium to long-term horizon.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-10-05 | Hold | Sell | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-09-17 | — | Hold | Weak fundamentals and high risk limit upside potential. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-09-16 | UBS | Rating Upgraded | — → 8 | 5.02 |
| 2026-09-16 | Barclays | Update | — → 8 | 5.02 |
| 2025-12-08 | Barclays | Update | — → 5 | 5.45 |
| 2025-12-03 | Morgan Stanley | Target Lowered | 14 → 10 | 4.6 |
| 2025-11-18 | UBS | Target Lowered | 13 → 10 | 5.11 |
| 2025-11-04 | Northland Securities | Target Lowered | 28 → 10 | 4.925 |
| 2025-11-04 | Deutsche Bank | Update | — → 8 | 5.03 |
